Introduction {#Sec1}
============

Actinobacteria are a phylum of Gram-positive bacteria renowned for the capability to produce secondary metabolites. A large number of structurally diverse natural products have been isolated from various Actinobacteria strains over the decades. Some of the natural products have become the essential part of our arsenal for treating infectious and chronic diseases. Accumulating genomic sequencing data reveals that even some of the best-studied Actinobacteria strains harbor many cryptic secondary biosynthetic gene clusters^[@CR1],[@CR2]^. With more and more researchers adopting a genome-guided approach and focusing on the activation of cryptic biosynthetic gene clusters, it is expected that Actinobacteria will continue to be a rich source of novel bioactive compounds.

Actinobacteria produce a superfamily of macrolactams using polyketide biosynthetic pathways. Within the macrolactam superfamily, there is a structurally distinct group of macrolactams containing a polyene skeleton and a nitrogen-containing moiety derived from L-glutamate via a β-amino acid starter unit (Fig. [1](#Fig1){ref-type="fig"}). This group of polyene macrolactams can be further divided into two subgroups according to the different β-amino acid starter units. Members of the first subgroup are synthesized using a (2S, 3S)-3-methylaspartate (3-meAsp) as starter unit^[@CR3]--[@CR6]^; whereas members of the second subgroup are synthesized using a 3-aminobutyrate as starter unit^[@CR7]--[@CR9]^. Both 3-meAsp and 3-aminobutyrate are synthesized from L-glutamate by dedicated pathways. The biosynthetic gene clusters (BGC) for vicenistatins, micromonosporin A, lobosamide A and mirlactam A have been identified and the biosynthetic mechanisms have been proposed^[@CR4],[@CR8]--[@CR11]^. The proposed biosynthetic mechanisms share some common features, with the macrolactam skeleton assembled by a type I modular PKS system from the L-glutamate-derived starter unit and malonyl-CoA or methylmalonyl-CoA extender units. The PKS product undergoes cyclization and tailoring to yield the final macrolactam. The so-called collinearity rule^[@CR12],[@CR13]^ for polyketide biosynthesis is strictly followed in the reported biosynthetic mechanisms. Structural diversity in the polyene macrolactams is generated via the utilization of different starter units (i.e. 3-meAsp or 3-aminobutyrate), varying composition of PKS modules and different tailoring enzymes.Figure 1Polyene macrolactams that contain a nitrogen-containing moiety derived from L-glutamate via a β-amino acid starter unit. All the representative polyene macrolactams shown here are produced by members of the *Streptomyces* genus with the exception of micromonolactam and macrotermycin A, which are produced by *Micromonospora* and *Amycolatopsis* strains respectively.

Here we report a biosynthetically talented *Streptomyces* strain (*Streptomyces* sp. SD85) isolated from the sediment sample collected from a coastal mangrove forest of Singapore. Among the secondary metabolites produced by *Streptomyces* sp. SD85, we isolated and identified sceliphrolactam, a polyene macrolactam that shares structural similarity and potentially similar biosynthetic mechanism with vicenistatin and some other known macrolactams. Genome sequencing and gene inactivation experiments allowed us to identify the putative sceliphrolactam BGC to reveal the enzymes involved in the synthesis of the macrolactam scaffold and starter moiety, and a potentially iterative mechanism in the biosynthesis of the macrolactam polyene scaffold.

Results and Discussion {#Sec2}
======================

*Streptomyces* sp. SD85 produces sceliphrolactam and other secondary metabolites under lab cultivation conditions {#Sec3}
-----------------------------------------------------------------------------------------------------------------

*Streptomyces* sp. SD85 is one of the Actinobacteria strains that we isolated from sediment samples collected from the mangrove forest of Sungei Buloh Wetland Reserve, Singapore. After the cultivation in GYM *Streptomyces* medium, the secondary metabolites produced by *Streptomyces* sp. SD85 were extracted from the culture broth and mycelium using ethyl acetate and methanol respectively. The secondary metabolites were subsequently profiled using liquid chromatography couple with high-resolution mass spectrometry (LC-HRMS). Aided by an in-house natural product library, we identified several known compounds that include streptorubin B (a member of prodiginine family, *m/z* = 392.2694 \[M + H\]^+^, calcd m/z = 392.2701 \[M + H\]^+^), 6,8-O-dimethylreticulol (*m/z* = 251.0916 \[M + H\]^+^, calcd m/z = 251.0919 \[M + H\]^+^), 6-O-dimethylreticulol (*m/z* = 237.0760 \[M + H\]^+^, calcd m/z = 237.0763 \[M + H\]^+^), filipin III (*m/z* = 655.4048 \[M + H\]^+^, calcd m/z = 655.4057 \[M + H\]^+^) and factumycin (*m/z* = 801.4301 \[M + Na\]^+^, calcd m/z = 801.4302 \[M + Na\]^+^). The red pigment streptorubin B is produced in abundance and accounts for the red/orange appearance of the colonies (Fig. [S1](#MOESM1){ref-type="media"}). In addition, *Streptomyces* sp. SD85 produces several potentially new compounds whose spectral signatures were not found in the database. The structure for one of the "unknown" compounds was established using HRMS and NMR spectroscopy (Figs [S4](#MOESM1){ref-type="media"}--[S10](#MOESM1){ref-type="media"}, Table [S1](#MOESM1){ref-type="media"}). This compound, which was isolated from the mycelium, turned out to be sceliphrolactam (*m/z* = 482.2532 \[M + H\]^+^, calcd for C28H35NO6, 482.2542 \[M + H\]^+^), which is a 3-amino-2-methylpropionate-containing polyene macrolactam that was isolated recently from a wasp-associated *Streptomyces* strain^[@CR11]^.

Complete genome sequencing suggests that *Streptomyces* sp. SD85 is a biosynthetically talented strain {#Sec4}
------------------------------------------------------------------------------------------------------

The biosynthetic pathway for sceliphrolactam has not been elucidated as of today. To identify the sceliphrolactam BGC and to further assess the biosynthetic potential of *Streptomyces* sp. *SD85*, we first obtained a draft genome using Illumina sequencing technology. Considering that the short reads from Illumina sequencing may cause mis-assembly, we re-sequenced the genome for the second time using the single molecule real time sequencing (SMRT®) technology (PacBio) to obtain the complete genome. The complete genome, which is highly similar to the draft genome except for the gap regions, revealed that the chromosome consists of 8,625,724 base pairs with an average GC content of 72.3%. Phylogenetic analysis based on 16 S rDNA sequences suggests *S. hiroshimensis* NBRC 3839(T) as the closest relative with a shared nucleotide identity of 99.52%.

AntiSMASH^[@CR14]^ analysis using AntiSMASH 3.0 suggested that the genome contains at least 52 BGCs for the biosynthesis of different classes of secondary metabolites. The 52 BGCs occupy a total of 1.82 Mb and constitute 21.2% of the genome, which is higher than the 10.8% and 16.6% occupancy for *S. coelicolor* and *S. avermitilis*^[@CR15],[@CR16]^. Similar to the *S. coelicolor* and some other *Streptomyces* strains, most of the BGCs reside in the two subtelomeric regions of the genome (Fig. [2A](#Fig2){ref-type="fig"}). More than half of the BGCs are predicted to produce polyketide and ribosome or non-ribosome peptide-derived secondary metabolites (Table [1](#Tab2){ref-type="table"}). Seventeen BGCs have genes that encode type I, II or III PKS systems, including three type I modular PKS systems. Ten BGCs possess genes predicted to produce lantipeptide, thiopeptide or lasso-peptides; and eleven BGCs contain non-ribosomal peptide synthetase (NRPS) proteins. A few terpene BGCs were identified as evidenced by the presence of terpene synthase genes. Several BGCs are considered to be hybrid BGCs containing genes that code for more than one type of scaffold-synthesizing enzymes (Table [1](#Tab2){ref-type="table"}). Considering that fewer than ten secondary metabolites were detected in our LC/MS-based metabolite profiling, some of the BGCs could be suppressed due to transcriptional or translational regulation.Figure 2Complete genome of *Streptomyces* sp. SD85 and the PKS-based biosynthetic gene clusters (BGCs) with confirmed products. (**A**). Circular representation of *Streptomyces* sp. *SD85* chromosome. The inner ring shows a normalized GC skew plot and the center ring depicts a normalized GC content plot. The outer ring shows the distribution of secondary biosynthetic gene clusters (represented by the bars). (**B**) Comparison of the putative filipin, Streptorubin B (a prodiginine) and factumycin gene clusters from *Streptomyces* sp. SD85 with characterized homologous gene clusters from other *Streptomyces* strains. (**C**) Organization of the putative sceliphrolactam gene cluster (See Table [2](#Tab1){ref-type="table"} for detailed gene annotation). (**D**) Homologous gene clusters identified in three other *Streptomyces* strains.Table 2Predicted function of the genes from the sceliphrolactam BGC.GeneProtein LengthClosest homolog \[source\]Identity/Similarity (%)Predicted functionUniProt ID*sceA*456Integral membrane transporter \[*Streptomyces* sp. 769\]79/88MFS transporterA0A0A8EUD2*sceB*384Thioredoxin \[*Burkholderia cenocepacia* KC-01\]45/58Electron transfer proteinV4ZEC6*sceC*73Ferredoxin \[*Saccharothrix* sp. ST-888\]61/82Electron transfer proteinA0A0F0HKK3*sceD*406Cytochrome P450 \[*Streptomyces* sp. SirexAA-E / ActE\]81/87Cytochrome P450 monooxygenaseG2NJJ2*sceE*404Cytochrome P450 hydroxylase \[*Streptomyces hygroscopicus subsp. jinggangensis* 5008\]81/88Cytochrome P450 monooxygenaseH2JPQ4*sceF*298Amino acid amidase \[*Saccharothrix* sp. ST-888\]81/89PeptidaseA0A0F0HK57*sceG*314ACP S-malonyltransferase \[Saccharothrix sp. ST-888\]79/86Acyl carrier protein aminoacyltransferaseA0A0F0HLD6*sceH*87Phosphopantetheine-binding protein \[*Saccharothrix* sp. ST-888\]69/77Acyl carrier proteinA0A0F0HNA7*sceI*508ATP-dependent synthetase \[*Saccharothrix* sp. ST-888\]80/86ATP-dependent aminoacyl-ACPA0A0F0HHV6*sceJ*512Peptide synthetase \[*Saccharothrix sp. ST-888*\]80/87ATP-dependent aminoacyl-ACPA0A0F0HNB1*sceK*413Decarboxylase \[*Saccharothrix* sp. ST-888\]80/89DecarboxylaseA0A0F0HI66*sceL*163Methylmalonyl-CoA mutase \[*Saccharothrix* sp. ST-888\]75/86Glutamate mutase S subunitA0A0F0HK60*sceM*432Glutamate mutase E-chain \[*Streptomyces hygroscopicus subsp. jinggangensis* 5008\]75/83Glutamate mutase E subunitH2JPP6*sceN*3626Modular polyketide synthase \[*Streptomyces hygroscopicus subsp. jinggangensis 5008*\]69/76Polyketide synthaseH2JPP5*sceO*3508Modular polyketide synthase \[*Streptomyces hygroscopicus subsp. jinggangensis* 5008\]74/81Polyketide synthaseH2JPP4*sceP*926LuxR family transcriptional regulator \[*Streptomyces roseochromogenus subsp. oscitans* DS 12.976\]57/70LuxR family transcriptional regulatorV6KW85*sceQ*1824Polyketide synthase \[*Saccharothrix* sp. ST-888\]79/85Polyketide synthaseA0A0F0HIL7*sceR*1582Beta-ketoacyl synthase \[*Saccharothrix* sp. ST-888\]77/85Polyketide synthaseA0A0F0HP09*sceS*5150Modular polyketide synthase \[*Streptomyces hygroscopicus subsp. jinggangensis* 5008\]73/80Polyketide synthaseH2JPR4*sceT*1294Modular polyketide synthase \[*Streptomyces hygroscopicus subsp. jinggangensis* 5008\]73/81Polyketide synthaseH2JPR3*sceU*81Uncharacterized protein \[*Streptomyces roseochromogenus subsp. oscitans* DS 12.976\]55/69UnknownV6KW03*sceV*266ABC transporter \[*Saccharothrix* sp. ST-888\]87/92ABC transporterA0A0F0HJ95*sceW*840ABC transporter permease \[*Streptomyces* sp. PBH53\]68/80ABC transporter permeaseA0A0H4C931*sceX*433Histidine kinase \[*Saccharothrix* sp. ST-888\]77/83Histidine kinaseA0A0F0HHC4*sceY*214LuxR family transcriptional regulator \[*Streptomyces roseochromogenus subsp. oscitans* DS 12.976\]87/94LuxR-family transcriptional regulatorV6KY34Table 1AntiSMASH-predicted BGCs for *Streptomyces* sp. SD85.BGCPositionProduct/typeFromToCluster 1128373191397NRPSCluster 2191639228433LantipeptideCluster 3254893292628T3PKSCluster 4338768374816ThiopeptideCluster 5449647472959LantipeptideCluster 6544798631900FilipinsCluster 7632222683087NRPSCluster 8752764792909PhosphonateCluster 9814767848264NRPSCluster 1010793831094356TerpeneCluster 1112376861312223SceliphrolactamCluster 1213686331383668NRPSCluster 1314604701474512NRPS-T1PKSCluster 1415442881554571BacteriocinCluster 1515880341600491TerpeneCluster 1616468631698126NRPS-T1PKSCluster 1717149381736137TerpeneCluster 1821354762146348BacteriocinCluster 1921703082196218SiderophoreCluster 2021964852241910T3 PKS-TerpeneCluster 2123658892376287EctoineCluster 2228296832850624LantipeptideCluster 2331251893133324MelaninCluster 2442265864269086T2 PKSCluster 2544761314497579LassopeptideCluster 2646248644667988T3 PKSCluster 2749859545012231LantipeptideCluster 2856345285639110MelaninCluster 2959993426017297SiderophoreCluster 3065044886559786NRPSCluster 3166704086706365ProdiginineCluster 3267344976758278TerpeneCluster 3367794446838577T1 PKS-TerpeneCluster 3468386266874184NRPSCluster 3569481576973315LantipeptideCluster 3671694697244251PKS/FASCluster 3772486717339459FactumycinCluster 3873635917384450LassopeptideCluster 3975685567585720TerpeneCluster 4076118127663138NRPSCluster 4176957747723406LantipeptideCluster 4278050557854201T1 PKS-TerpeneCluster 4379977438031379NRPS-T1 PKSCluster 4480834628121926NRPSCluster 4581256328127719γ-ButyrolactoneCluster 4681280248185901PKS/FASCluster 4782513158271035TerpeneCluster 4882743628305247TerpeneCluster 4983124768367627PKS/FASCluster 5084098818446192UnknownCluster 5184655118538072PKS/FASCluster 5285492858564374Lantipeptide

For PKS and NRPS proteins to be enzymatically active, the carrier protein domains of the PKS and NRPS proteins must undergo phosphopantetheinylation, a post-translational modification catalyzed by Sfp or AcpS-type 4'- phosphopantetheinyl transferases (PPTase)^[@CR17],[@CR18]^. The *Streptomyces* sp. SD85 genome harbors at least three genes encoding Sfp-type PPTases and one gene-encoding AcpS-type PPTase. All four PPTases are predicted to be discrete proteins with none of them integrated into the PKS or NRPS proteins as observed for some PKSs^[@CR19]^.

Identification of sceliphrolactam BGC by gene inactivation {#Sec5}
----------------------------------------------------------

With the complete genome in hand, the sceliphrolactam-producing *Streptomyces* sp. SD85 strain provides us with an opportunity to identify the sceliphrolactam BGC and decipher the biosynthetic pathway. As the macrolactam skeleton of sceliphrolactam is most likely generated by a type I modular PKS system, we first searched BGCs that contained type I modular *pks* genes. The genome of *Streptomyces* sp. SD85 harbors several BGCs that are predicted to contain type I *pks* or *fas* (fatty acid synthase) genes, but only three (BGC6, 11 and 37 (Table [1](#Tab2){ref-type="table"})) encode type I modular PKS systems. Based on the high similarity shared with the BGCs from the MIBiG database^[@CR14]^, BGC6 and BGC37 are predicted to produce filipins and kirromycin respectively (Fig. [2B](#Fig2){ref-type="fig"})^[@CR20]--[@CR22]^. Assignment of the two BGCs is consistent with the detection of filipin III and factumycin (a close structural analogue of kirromycin)^[@CR23]^ in the culture broth. BGC11 encodes six PKS proteins and a dozen of other enzymes, transporters and regulatory proteins (Fig. [2C](#Fig2){ref-type="fig"}). Three uncharacterized BGCs that share high similarity with BGC11 were also found in the genomes of *Streptomyces* sp. SirexAA-E*, Streptomyces* sp. PAMC26508 *and S. flavogriseus* ATCC3331 (Fig. [2D](#Fig2){ref-type="fig"}).

To find out whether BGC11 is responsible for sceliphrolactam biosynthesis, we used a CRISPR/Cas9 strategy to delete an internal fragment of the *sceN* gene, which encodes the first of the six PKS modules. The pCRISPR-Cas9 plasmid was employed to express Cas9, sgRNA and a DNA template required for homology directed repair (HDR)^[@CR24]^. After cloning the sgRNA and homologous DNA sequences into the pCRISPR-Cas9 plasmid, we transformed *Streptomyces* sp. SD85 with the modified plasmid by the *E. coli - Streptomyces* conjugation method^[@CR24]^. After Cas9-mediated DNA cleavage and repair, DNA gel analysis and DNA sequencing confirmed that a portion of *sceN* was successfully deleted (Fig. [3A,B](#Fig3){ref-type="fig"}). It should be noted that we used five sgRNAs to target different protospacer adjacent motif (PAM) sites within the *sceN* gene and only one of the sgRNAs (sgRNA2) led to DNA cleavage and repair (Fig. [3B](#Fig3){ref-type="fig"}). As already documented by other researchers, the efficiency of Cas9/sgRNA-mediated gene deletion in bacteria can vary greatly^[@CR25]^. Subsequent metabolite analysis by HPLC confirmed the absence of sceliphrolactam in the culture broth of the *∆sceN* mutant strain (Fig. [3C](#Fig3){ref-type="fig"}). The gene inactivation experiment supports that the *sce* BGC encodes the enzymes and other proteins required for sceliphrolactam biosynthesis. This conclusion is further reinforced by the sequence similarity shared by the biosynthetic genes between *sce* and the vicenistatin BGC as discussed below.Figure 3Inactivation of sceliphrolactam biosynthetic gene *sceN* using CRISPR/Cas9-based method. (**A**) Schematic illustration of the CRISPR/Cas9-mediated cleavage of genomic DNA and homology directed repair (HDR) to delete part of *sceN*. (**B**) PCR results confirmed the deletion of 883 base pairs of *sceN* using sgRNA2 as guide. A full-sized image of the DNA gel is included in the supporting information. (**C**) HPLC analysis of the *∆sceN* mutant strain to show the abolishment of sceliphrolactam production. The sceliphrolactam peak is indicated by the arrow. The wavelength (λ) was set at 330 nm for the HPLC detector (Inset: on-line absorption spectrum of sceliphrolactam).

Annotation of non-PKS biosynthetic genes in the sce gene cluster {#Sec6}
----------------------------------------------------------------

In addition to the five PKS-encoding genes, the *sce* BGC also contains other genes predicted to code for non-PKS enzymes, membrane-embedded ABC transporters and two LuxR-type transcriptional regulators. The predicted functions of the biosynthetic enzymes, transporters and regulatory proteins are summarized in Table [1](#Tab2){ref-type="table"}. Here we describe that the annotation of the *sce* genes provides further support for the involvement of the *sce* BGC in sceliphrolactam biosynthesis.

The *sce* gene cluster has several genes (*sceG-N*) that share homology with a set of genes found in *S. halstedii* HC-34 for vicenistatin biosynthesis (Fig. [4A](#Fig4){ref-type="fig"}). This set of genes (*vinH-O*) is responsible for the synthesis of the 3-amino-2-methylpropionate moiety of vicenistatin from L-glutamate via 3-MeAsp^[@CR3],[@CR26]^. Similar to vicenistatin, sceliphrolactam also contains a 3-amino-2-methylpropionate moiety. Considering the high sequence homology shared by the two sets of genes, the 3-amino-2-methylpropionate moiety of sceliphrolactam is likely to be synthesized by a similar pathway. Based on the function of starter-synthesizing enzymes in vicenistatin biosynthesis^[@CR27]^, SceL and SceM, which are the homologs of VinH (Identity/Similarity: 57%/74%) and VinI (Identity/Similarity: 62%/70%), are likely to form a coenzyme B~12~-dependent glutamate mutase that catalyzes the transmutation of glutamate (Fig. [4B](#Fig4){ref-type="fig"}**)**. SceI, a homolog of VinN (Identity/Similarity: 61%/75%), is predicted to transfer 3-methylaspartate onto the carrier protein SceH (homolog of VinL: Identity/Similarity: 64%/75%). SceK is the homolog of VinO (Identity/Similarity: 67%/79%) and is likely to catalyze the decarboxylation and epimerization of SceH-tethered 3-methylaspartate to 3-amino-2-methyl propionate; whereas SceJ (VinM homolog, Identity/Similarity: 58%/67%) is likely to catalyze the formation of an amide to protect the reactive amino group. SceG shares high sequence homology with the aminoacyltransferase VinK (Identity/Similarity: 69%/86%), with all the catalytic residues of VinK conserved^[@CR28]^. Accordingly, SceG is likely responsible for transferring the 3-amino-2-methylpropionate group from SceH onto the ACP of the loading module of SceN^[@CR26],[@CR29]^.Figure 4Proposed biosynthetic mechanism for sceliphrolactam. (**A**) BGCs of sceliphrolactam and vicenistatin share a set of genes (*sceG-M vs. vinH-O*) for β-amino acid starter unit biosynthesis. (**B**) Overall biosynthetic mechanism for sceliphrolactam. The presence of a *cis*-double bond between the protons of C14 and C15 was confirmed by ^1^H NOESY correlation (Fig. [S10](#MOESM1){ref-type="media"}). The stereochemistry of C-11 was assigned based on the observation that the KR~6~ domain is a B-type KR domain^[@CR49]--[@CR51]^. (**C**) A possible mechanism with SceQ containing the iterative module. (**D**) A possible mechanism with SceR containing the iterative module. (ACP: acyl carrier protein; AT: acyltransferase; DH, dehydratase; KR; ketoreductase; KS, ketosynthase; TE, thioesterase).

Apart from the starter biosynthetic genes, *sceF* encodes a protein (SceF) that shares high similarity with VinJ (Identity/Similarity: 71%/84%), an amidohydrolase or peptidase in vicenistatin biosynthesis^[@CR26],[@CR30]^. VinJ, which is distinct from other more common serine peptidases adopting an α/β hydrolase fold, plays a role by catalyzing the amide hydrolysis to generate the free amino group, which must be protected during the polyketide chain extension to prevent premature cyclization of intermediates^[@CR29]^. Hence, the protection de-protection strategy for the reactive aminoacyl-ACP intermediates found in the biosynthesis of vicenistatin, amino marginolactone^[@CR31]^ and other natural products is most likely to be shared by sceliphrolactam biosynthesis. In addition, the presence of two cytochrome P450 genes (*sceD* & *secE*) in the BGC is also consistent with the two hydroxylated carbon atoms (C-10 and C-12) in sceliphrolactam (Fig. [4B](#Fig4){ref-type="fig"}). The genes *sceA* and *sceB* encode a pair of thioredoxin and ferredoxin, which are likely to be the electron transfer proteins that supply electrons to the cytochrome P450 hydroxylases.

Analysis of the Sce type I modular PKS {#Sec7}
--------------------------------------

We performed detailed sequence analysis on the acyltransferase (AT), ketosynthase (KS), ketoreductase (KR) and dehydratase (DH) domains of all ten PKS modules encoded by the *sce* gene cluster. All AT, KS, KR and DH domains contain the essential catalytic residues and are predicted to be catalytically active. The substrate preference of AT domains of type-I PKS towards malonyl-CoA or methylmalonyl-CoA is defined by several key residues in the substrate binding pocket^[@CR32]--[@CR34]^. Sequence comparison suggests that the two AT domains from module-3 and module-8 are likely to use methylmalonyl-CoA as substrate. This is in accordance with the two methyl groups (C-26, C-27) in sceliphrolactam (Fig. [4B](#Fig4){ref-type="fig"}). Meanwhile, protein sequence analysis suggests that the KR domains belong to the "B-type" KR that contains a conserved (L/V)D(D/N) motif, which is crucial for guiding polyketide intermediates into the active site of KR domains to produce "R"-configured β-hydroxyl groups (Fig. [S2](#MOESM1){ref-type="media"}).

To assemble the macrolactam skeleton of sceliphrolactam, the modular PKS system is expected to have eleven modules to join the 3-amino-2-methylpropionate starter unit with nine acetyl and two propionyl extender units. Surprisingly, the *sce* BGC only encodes ten PKS modules found in SceN, SceO, SceQ, SceR and SceS. According to the collinearity rule for PKS^[@CR12],[@CR13]^, the order of PKS modules in the biosynthetic complex should be reflected in the chromosomal order of the *pks* genes. Considering the collinearity rule is strictly followed in the biosynthesis of other known macrolactam polyenes, the Sce PKS system could represent a deviation from the orthodox systems and may feature an iterative module (Fig. [4C,D](#Fig4){ref-type="fig"}) we will discuss further below. To confirm that the shortage of a module is not because of erroneous assembly of the genome sequence, DNA segments at the boundaries of s*ceO, sceQ*, *sceR* and *sceS* genes were amplified by PCR (Fig. [S3](#MOESM1){ref-type="media"}). The result confirms that the four genes form a continuous DNA fragment, and thus, rules out the existence of a gene encoding a "missing" module. Meanwhile, we did not detect other macrolactams in the biomass or culture broth of *Streptomyces* sp. SD85, which makes it tenuous to argue that sceliphrolactam is a minor product generated by the aberrant stuttering of a PKS module.

Evidence disfavoring the involvement of a trans-PKS module in sceliphrolactam biosynthesis {#Sec8}
------------------------------------------------------------------------------------------

There is a plausible explanation for the shortage of a PKS module in the Sce system without invoking the breakdown of the collinearity rule. This would involve the use of a *trans*-PKS module encoded by another gene located somewhere else in the genome. This *trans*-PKS module must be integrated into the mega-PKS protein complex by docking specifically between SceQ and SceR. Considering that the β-keto group remains unreduced for the chain extension catalyzed by the mysterious module, a potential *trans*-PKS module is most likely to have a KS-AT-ACP domain composition and contain docking domains that are compatible with the docking domains of SceR and SceQ. However, an inspection of the complete genome of *Streptomyces* sp. SD85 revealed that all the *pks* genes in the genome are accounted for by the 52 BGCs. We could not find any orphan PKS module with docking domains, let alone an orphan module with the KS-AT-ACP domain organization. We also searched the genome of the three *Streptomyces* strains that contain the homologous *sce* BGCs (Fig. [2C](#Fig2){ref-type="fig"}) and did not find such orphan PKS module. Moreover, we identified the N- and C-terminal portions of SceN, SceO, SceQ, SceR and SceS that are predicted to fold into docking domains crucial for holding the PKS complex together (Fig. [S13](#MOESM1){ref-type="media"})^[@CR35]^. The lack of a gene that encodes a potential *trans*-PKS module and the presence of compatible docking domains for SceR and SceQ seem to argue against the participation of a *trans*-PKS module.

To seek experimental evidence for or against the involvement of a *trans* PKS module, we constructed a mutant strain by fusing the *sceQ* and *sceR* genes on the chromosome. The rationale behind the experiment is that when the *sceQ* and *sceR* genes are fused, SceQ and SceR will be expressed as a single protein to prevent the insertion of any potential *trans*-PKS module. Production of sceliphrolactam is expected to be abolished for the fusion mutant because the *trans*-PKS module can no longer dock between the closely linked SceQ and SceR. Similar gene fusion experiment has been used to support an iterative mechanism in the biosynthesis of borrelin^[@CR36]^. To create the *sceQ-R* fusion mutant, a pCRISPR-cas9 plasmid that harbors two sgRNA cassettes was constructed to target the *sceQ/sceR* intergenic region for the deletion of 14 base pairs (Fig. [5A](#Fig5){ref-type="fig"}). Deletion of the 14 base pairs was expected to remove the stop and start codons and lead to the fusion of *sceQ* and *sceR* genes. The sgRNA and homology template-containing pCRISPR-cas9 plasmid was transformed into *Streptomyces* sp. SD85 strain using the same *E. coli* - *Streptomyces* conjugation method as the gene inactivation experiment described earlier. Deletion of the 14 base pairs was confirmed by gene sequencing for the four colonies we tested (Fig. [5B](#Fig5){ref-type="fig"}). After cultivating the *sceQ-R* fusion mutant strains inoculated using four positive colonies, we found that sceliphrolactam was still produced by all four mutant strains, despite at a lower yield than the wild type strain (Fig. [5C](#Fig5){ref-type="fig"}). The results suggest that the polyketide intermediate is passed from SceQ directly to SceR, and thus, it is tenuous to argue that a *trans*-PKS module is involved in the biosynthesis of sceliphrolactam.Figure 5(**A**) Schematic illustration of the CRISPR/Cas9-mediated and dual sgRNA-guided DNA cleavage to fuse the *sceQ* and *sceR* genes. (**B**) DNA sequencing result confirmed the fusion of the two genes upon the deletion of 14 base pairs (sequence in red). (**C**) HPLC analysis comparing the production of sceliphrolactam between the *sceQ-R* fusion mutant and the wild type *Streptomyces* sp. SD85. The sceliphrolactam peak is indicated by the arrow. The wavelength (λ) was set at 330 nm for the HPLC detector.

A potential biosynthetic mechanism that involves an iterative PKS module {#Sec9}
------------------------------------------------------------------------

As the experimental evidence argue against the involvement of a *trans*-PKS module, the apparent lack of a PKS module in the biosynthesis of sceliphrolactam remains to be fully explained. One of the conceivable mechanisms involves the iterative use of a PKS module. The iterative use of modules in PKS systems is increasingly known as a common phenomenon and has been reported in the biosynthesis of lankacidin^[@CR37]^, borrelidin^[@CR38]^, aureothin^[@CR39]^, stigmatellin^[@CR40]^ and other polyketide secondary metabolites^[@CR41]^. There are two possibilities, with either SceQ or SceR acting iteratively (Fig. [4C,D](#Fig4){ref-type="fig"}). If SceQ acts iteratively, the β-keto group is reduced in the first chain-extension cycle to generate a hydroxyl group that is subsequently dehydrated, but remains unreduced in the second cycle. On the other hand, if SceR acts iteratively, the β-keto group is not reduced in the first chain-extension cycle; but reduced to yield hydroxyl group in the second cycle. Regardless of which module acts iteratively, the iterative module seems to be "programmed" with the activity of the KR domain switching on and off in two successive extension cycles. Hence, in comparison with most known iterative mechanisms that involve modules acting iteratively with the processing domains (e.g. KR, DH, ER or MT) generating the same chemical outcome in each extension cycle, the putative iterative module in sceliphrolactam biosynthesis is able to generate different outcome during the two successive extension cycles. Such "programmed iteration" is rare but not unprecedented. It was recently found that the biosynthesis of azalomycin involves a similar iterative module. This iterative module contains an ER domain whose activity can be "toggled" off and on to ensure that the ER domain only functions in the second extension cycle^[@CR31],[@CR42]^. The selective keto-reduction on different polyketide intermediates by the SceQ or SceR module is also reminiscent of the programmed keto-reduction mechanism observed in partially reducing iterative PKSs^[@CR32],[@CR43]--[@CR45]^.

In summary, we have isolated and characterized a biosynthetically talented *Streptomyces* strain that harbors a large number of uncharacterized biosynthetic gene clusters. As an effort to explore the biosynthetic potential of the strain, we identified all the modular PKS-based BGCs and their products. For the polyene macrolactam sceliphrolactam, identification of the *sce* BGC suggests a potentially unique modular PKS system for macrolactam biosynthesis. Our experimental data suggest that the biosynthesis of sceliphrolactam potentially involves a "programmed" iterative PKS module. Among all the known polyene macrolactams, sceliphrolactam is the only one that features a biosynthetic mechanism that does not seem to follow the co-linearity rule by involving an iterative PKS module. Future mechanistic studies are required to identify which module acts iteratively and understand how the iterative domain achieves the programmed keto-reduction.

Experimental Procedures {#Sec10}
=======================

*Streptomyces* sp. SD85 isolation and maintenance {#Sec11}
-------------------------------------------------

*Streptomyces* sp. SD85 was isolated from marine sediment samples collected from the Sungei Buloh Wetland Reserve, Singapore. The sediment samples were collected from the sediment (1--2 meter depth) in the mangrove swamps to harvest the microbial communities from the submerged sediment. The sediment samples were rinsed and filtered after being air dried and treated with microwave irradiation. With the filtrate, a series of 10-fold dilutions were performed and a total of 0.1 mL from each dilution was plated onto the International *Streptomyces* Project (ISP3) medium plate. 30 μg/mL Cycloheximide and 25 μg/mL nalidixic acid were used to inhibit fungal and fast growing Gram-negative bacteria. All culture plates were incubated for up to three weeks. Individual colonies were obtained after a few rounds of streaking and the strain was maintained in GYM medium agar (4 g/L glucose, 4 g/L yeast extract, 10 g/L malt extract, 20 g/L agar, pH 7.2) at 28 °C.

Complete genome sequencing {#Sec12}
--------------------------

High quality genomic DNA was extracted using a modified genomic DNA extraction protocol for *Streptomyces*^[@CR46]^. The genomic DNA was first sequenced using illumine technology to obtain a draft genome which contains large gaps. Then the complete genome sequence of *Streptomyces* sp. SD85 was obtained using Single Molecule Real Time (SMRT) sequencing technology (Pacific Biosciences, California, USA). We sequenced the genome on a PacBio RS II platform. 1 SMRT cell was used and the sequencing run was performed 3 times. The PacBio long sequencing reads have reached an approximate 114 X coverage of the genome, and were successfully assembled into a linear chromosome with a size of 8,625,764 bp by using the Hierarchical Genome Assembly Process 2 (HGAP2) protocol from SMRT Analysis version 2.0. The DNA sequences for the sceliphrolactam biosynthetic gene cluster obtained from illumina and PacBio sequencing are identical and have been deposited in GenBank (Accession number: KX230849). For Illumina MiSeq sequencing, a total of 3,906,106 reads were obtained with an average read length of 145.17 bases. 3,896,491 reads were matched with an average length of 145.34 bases. Sequencing reads were trimmed and *De novo* assembly was performed using CLC Genomics Workbench (CLC bio, Denmark). A total of 112 contigs were obtained with an average length of 76,406 bases and a total length of 8,557,547 bases. For the long-read sequencing performed the PacBio technology, a single SMRT cell was used with a three sequencing runs. A read quality value of 84 was achieved with 86,939 zero-mode-waveguides (ZMWs), with average coverage value of 114.0. Mean polymerase read length was 15,610 bp with mean reads of inserts (ROI) readlength value of 13,164 bp. A single contig of length 8,625,764 bases was obtained after assembly.

Profiling of secondary metabolites in the culture broth and mycelia of Streptomyces sp. SD85 {#Sec13}
--------------------------------------------------------------------------------------------

*Streptomyces* sp. 85 was cultured in GYM liquid medium (100 mL in 500 mL baffled Erlenmeyer flask) for 96 hr at 28 °C. Mycelia were separated from culture broth by centrifugation. Mycelia and culture broth were extracted separately with methanol and ethyl acetate, respectively. The organic layers were dried under vacuum and re-dissolved in methanol. HPLC analysis of the crude extract was performed with Grace® VisionHT^TM^ C18-HL (4.6 mm × 250 mm, 5 µm) using an Agilent 1200 HPLC system equipped with DAD detector. A 60 min gradient elution at 1 mL/min was employed with 10% aqueous acetonitrile to 100% acetonitrile. Mobile phase solvents were supplemented with 0.1% formic acid. Analytes were monitored at λ = 220 nm, 280 nm, 330 nm, 400 nm. LC-MS was performed using Thermo Scientific Accela LC system coupled with an LTQ XL^TM^ Linear Ion Trap Mass Spectrometer. The conditions for LC were similar to those employed for HPLC-DAD analysis. Mass spectra were measured using positive and negative ion mode of ESI (capillary voltage 3.5 kV; cone voltages 30 V/50 V; source temperature 400 °C; cone gas flow 60 L/hr; desolvation gas flow 450 L/hr) with a mass range of 100--2000 Da and a scan time of 0.5 s.

Large-scale fermentation and isolation of sceliphrolactam {#Sec14}
---------------------------------------------------------

*Streptomyces* sp. SD85 was cultured in GYM liquid medium (800 mL in 2 L baffled Erlenmeyer flask) for 7 days at 29 °C, in the dark. Combined mycelia from four culture flasks were extracted with one liter of acetone twice. The organic layer was dried under vacuum to afford a crude extract (\~4 g). The extract was re-dissolved in 90% methanol and partitioned four times with equal volume of hexane to remove unwanted lipid material. The washed extract was subjected to semi-preparative reversed phase HPLC using Shimadzu Prominence Preparative HPLC system equipped with Zorbax Eclipse XDB C18 semi-prep column (9.4 mm × 250 mm, 5 µm). An isocratic solvent system of H~2~O:CH~3~OH (45:55) with a flow rate of 4.7 mL/min was used for compound isolation. Elution of the compounds was monitored at 333 nm and a peak corresponding to sceliphrolactam was observed at t = 22 min. Pure sceliphrolactam (2 mg/L) was obtained under dark conditions to minimize degradation of the polyene compound.

Construction of *Streptomyces* sp. SD85 ∆sceN mutants using CRISPR/Cas9 method {#Sec15}
------------------------------------------------------------------------------

Construction of the plasmid pCRISPR-Cas9-SceN for CRISPR/Cas9-mediated *sceN* gene mutation in *Streptomyces* sp. *SD85* was performed using pCRISPR-Cas9, which was a kind gift from Sang Yup Lee's lab in the Korea Advanced Institute of Science and Technology (KAIST). All cloning steps were carried out using *E. coli* TOP10 (Invitrogen, US). Identification of protospacer sequences in *sceN* was performed using the Benchling Server. Selected *sceN* DNA spacer was introduced into pCRISPR-Cas9 by ligating a PCR-generated sgRNA sequence into *Sna*BI and *Nco*I linearized pCRISPR-Cas9 vector. To generate an 883 bp deletion via homology directed repair, two DNA templates that are homologous to the 5′- and 3′- regions of the *sceN* gene and are 883 bp apart from each other were amplified from genomic DNA using Phusion® high fidelity DNA polymerase. The sceN spacer-containing pCRISPR-Cas9 was digested using *Stu*I restriction enzyme and jointed with the template DNA fragments using Gibson Assembly kit (New England BioLabs, US). The sgRNA and template-containing pCRISPR-Cas9 plasmid was introduced into the *Streptomyces* sp. SD85 parental strain by conjugation method using *E. coli* ET12567/pUZ8002 as described^[@CR47]^. Briefly, *Streptomyces* spores were collected from seven-day old culture grown on GYM agar containing 10 mM MgCl~2~ and 10 mM CaCl~2~, and subjected to heat shock at 45 °C for 5 min. They were allowed to germinate at 30 °C for 6 hr and mixed with an exponential phase culture of *E. coli* ET12567/pUZ8002 containing the modified pCRISPR-Cas9 plasmid at a donor to recipient ratio of 3:1. The resultant mixture was plated onto MS agar supplemented with 40 mM MgCl~2~ and 20 mM CaCl~2~, and incubated for 22.5 hr at 30 °C. One millilitre of sterile water containing 1 mg of apramycin and 500 µg of nalidixic acid was overlaid onto the plates for selection of successful exconjugants. Plates were further incubated at 30 °C for 4--5 days before exconjugants were picked onto fresh MS agar plates containing 40 μg/mL apramycin and 25 µg/mL nalidixic acid.

Exconjugants harbouring the modified pCRISPR-Cas9 plasmid were determined by colony PCR. True exconjugants were patched onto MS agar that contain 40 μg/mL apramycin and 10 μg/mL thiostrepton for induction of Cas9 expression. Clearance of plasmids was achieved by patching resultant colonies onto MS agar and incubating them at 37 °C for 4 days. Apramycin sensitivity was confirmed by replica plating onto selective and non-selective plates.

To screen for successful mutants, individual clones were cultured in liquid GYM at 30 °C for 3 days for genomic DNA isolation using a previously described protocol^[@CR48]^. Diagnostic PCR was performed to establish a deletion of 883 bp in the *sceN* gene.

CRISPR/Cas9 mediated sceQ-R gene fusion {#Sec16}
---------------------------------------

A dual sgRNA-containing pCRISPR-Cas9 plasmid was constructed by designing a dual sgRNA synthetic construct with a configuration of (*Nco*I site -- spacer - sgRNA1tracr -- terminator -*gapdhp* (EL) - spacer - sgRNAtracr -- *Sna*BI site). This construct was cloned into *Sna*BI and *Nco*I linearized pCRISPR-Cas9 vector by Gibson Assembly. The resulted plasmid was linearized using the *Stu*I restriction enzyme and ligated with the HDR template to yield the plasmid pCRISPR-cas9-dual-sceQR. Introduction of this plasmid into *Streptomyces sp. SD85* and subsequent induction of Cas9 expression was performed as described above. Successful mutant strains were validated by diagnostic PCR and sequencing of the fragments amplified from genomic DNA of individual clones.

HPLC analysis of sceliphrolactam production for the *Streptomyces* sp. SD85 ∆sceN and sceQ-R fusion mutants {#Sec17}
-----------------------------------------------------------------------------------------------------------

The mycelia of 7 days old wild-type (WT) *Streptomyces* sp. SD85 and the mutant strains were extracted twice with equal volume of acetone and dried under vacuum. The crude extracts were re-dissolved in methanol and subjected to HPLC analysis with an Agilent 1200 HPLC system equipped with DAD for UV detection. A Gradient elution program was employed, starting with 40% aqueous methanol at 0 min to 70% aqueous methanol at 50 min and 100% methanol at 60 min. The analytes were monitored at λ = 220 nm, 280 nm, 330 nm, 420 nm. Experiments were repeated twice to ensure reproducibility.

Accession code {#Sec18}
--------------

The BGC gene sequence has been deposited in public database (GenBank accession number: KX230849).
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